ConductScience.org, home

Gene · 10683

DLL3: delta like canonical Notch ligand 3

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. DLL3: delta like canonical Notch ligand 3. Genes, record 10683. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10683

On this page

Gene

Symbol
DLL3
HGNC
Name
delta like canonical Notch ligand 3
HGNC
NCBI Gene ID
10683
NCBI Gene
HGNC ID
HGNC:2909
HGNC
Ensembl
ENSG00000090932
NCBI Gene
Aliases
SCDO1
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q9NYJ7Delta-like protein 36180Ensembl, GeneID, HGNC

Source UniProt

Patents260

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4830720 A12026-10-281Q9NYJ7Espacenet
WO 2026193244 A12026-09-171Q9NYJ7Espacenet
EP 4794721 A12026-08-261885Q9NYJ7Espacenet
EP 4794721 A12026-08-261892Q9NYJ7Espacenet
JP 2026521512 A2026-06-301Q9NYJ7Espacenet
JP 2026521513 A2026-06-301Q9NYJ7Espacenet
JP 2026521249 A2026-06-291Q9NYJ7Espacenet
JP 2026048645 A2026-03-17255Q9NYJ7Espacenet
JP 2026508154 A2026-03-101Q9NYJ7Espacenet
US 12570741 B22026-03-1020Q9NYJ7Espacenet

1 to 10 of 260

See all 260 patents

Drugs2

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
ROVALPITUZUMAB TESIRINECHEMBL3990011Delta-like protein 3 binding agentBINDING AGENTChEMBL
TARLATAMABCHEMBL5095292Delta-like protein 3 binding agentBINDING AGENTChEMBL

Trials43

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07531095TARLATAMABPHASE1ClinicalTrials.gov
NCT07423585TARLATAMABPHASE2ClinicalTrials.gov
NCT07402343TARLATAMABPHASE2ClinicalTrials.gov
NCT07328490TARLATAMABPHASE1/PHASE2ClinicalTrials.gov
NCT07243470TARLATAMABPHASE1/PHASE2ClinicalTrials.gov
NCT07242547TARLATAMABPHASE2ClinicalTrials.gov
NCT07203053TARLATAMABPHASE2ClinicalTrials.gov
NCT07111507TARLATAMABPHASE2ClinicalTrials.gov
NCT07061080TARLATAMABPHASE2ClinicalTrials.gov
NCT07037758TARLATAMABPHASE1ClinicalTrials.gov

1 to 10 of 43

See all 43 trials

NIH grants1,404

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleDLL3 papersNewest fiscal year
P30CA008748Cancer Center Support Grant402025
P30CA016672Cancer Center Support Grant222025
U24CA213274Coordinating center for the NCI small cell lung cancer research consortium202025
P30CA016058Cancer Center Support Grant132025
R01CA207295DNA damaging therapy and immune response in small cell lung cancer subtypes122025
P50CA097186The Pacific Northwest Prostate Cancer SPORE112025
R35CA263816Novel therapeutic development for small cell lung cancer102025
R35CA232130Annotating Cancer Biology through Non-Invasive Molecular Imaging72025
R37CA241486Molecular mechanisms underlying lineage plasticity in prostate cancer72025
P01CA163227Androgen Receptor Action in Castration Resistant Prostate Cancer62025

1 to 10 of 1,404Source NIH's project files

See all 1,404 nih grants

Papers2,335

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
DLL3 expression predicts response and long-term outcome in small cell lung cancer patients treated with tarlatamab.bioRxiv202642818314PubTator, text miningPubMed
Antibody-Drug Conjugates in Lung Cancer: Promise, Progress, and Persistent Challenges.Curr Issues Mol Biol202642793224PubTator, text miningPubMed
Recent advances and future challenges of bispecific antibodies in lung cancer.Crit Rev Oncol Hematol202642778079PubTator, text miningPubMed
Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection.Front Immunol202642761714PubTator, text miningPubMed
γδ T cells modulate anti-tumor immunity in small cell lung cancer.Cancer Cell202642759517PubTator, text miningPubMed
Navigating tarlatamab and bispecific T-cell engager therapy in small cell lung cancer: A narrative review.Cancer Treat Res Commun202642753581PubTator, text miningPubMed
What are the Unmet Needs in Managing Digestive Neuroendocrine Carcinomas?Curr Oncol Rep202642747588PubTator, text miningPubMed
Immunohistochemical stratification of bladder small cell carcinoma reveals two major phenotypes with distinct therapeutic biomarker profiles.Histopathology202642747234PubTator, text miningPubMed
T-Cell Engagers in Lung Cancer: A Comprehensive Literature Review from Tarlatamab Approval to Next-Generation Strategies.Cancers (Basel)202642738247PubTator, text miningPubMed
Tarlatamab in Relapsed SCLC With Idiopathic Pulmonary Fibrosis: A Case With Comparative DLL3 Expression Analysis: Case Report.JTO Clin Res Rep202642733924PubTator, text miningPubMed

1 to 10 of 2,335

See all 2,335 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/10683

GET https://conductscience.org/api/genes/v1/10683/patents?page=2